Anticoagulant therapy is recommended for most patients with nonvalvular atrial fibrillation (NVAF) to reduce the risk of stroke and systemic embolism. Temporary interruption of oral anticoagulant drugs (OAC) in preparation for a procedure, is frequently necessary, most often to mitigate bleed risk with surgical or invasive procedures in these patients. In recent years, a lot of clinical studies related to periprocedural management of anticoagulant therapy for NVAF patients have been performed by specifical addressing:①whether or when anticoagulant therapy should be interrupted; ②whether or how anticoagulant bridging with a parenteral agent should be performed; ③when and how anticoagulant therapy should be restarted. Research status of periprocedural anticoagulation in NVAF patients will be reviewed in this article.